New hope for Tough-to-Treat breast cancer: Two-Drug attack targets hidden weakness

NCT ID NCT07193394

Summary

This study is testing whether a combination of two existing drugs, tucatinib and trastuzumab, can help control advanced breast cancer that has a specific genetic mutation (called HER3) but is not the usual HER2-positive type. It's for people whose cancer has grown despite trying at least two prior chemotherapy treatments. The goal is to see if this drug combo can shrink tumors or stop them from growing for a meaningful period of time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER ( HER2 NEGATIVE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de Nîmes

    NOT_YET_RECRUITING

    Nîmes, 30 029, France

    Contact

    Contact

  • Centre Antoine Lacassagne

    NOT_YET_RECRUITING

    Nice, 06 189, France

    Contact

    Contact

  • Centre Eugène Marquis

    NOT_YET_RECRUITING

    Rennes, 35 042, France

    Contact

    Contact

  • Chu Dupuytren- Limoges

    NOT_YET_RECRUITING

    Limoges, 87 042, France

    Contact

    Contact

  • Institut Curie_ Site Saint-Cloud

    RECRUITING

    Saint-Cloud, 92 210, France

    Contact

    Contact

  • Institut Paoli-Calmettes

    NOT_YET_RECRUITING

    Marseille, 13009, France

    Contact

    Contact

  • Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole Claudius Regaud

    NOT_YET_RECRUITING

    Toulouse, 31 059, France

    Contact

    Contact

  • Institut de Cancérologie de Lorraine

    NOT_YET_RECRUITING

    Vandœuvre-lès-Nancy, 54 519, France

    Contact

    Contact

  • Polyclinique Bordeaux Nord Aquitaine

    NOT_YET_RECRUITING

    Bordeaux, 33 300, France

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.